Sökning: WFRF:(Rives N) >
Cost-effectiveness ...
Cost-effectiveness evaluation of clobetasol propionate shampoo (CPS) maintenance in patients with moderate scalp psoriasis : A Pan-European analysis
-
Papp, K. (författare)
-
Poulin, Y. (författare)
-
Barber, K. (författare)
-
visa fler...
-
Lynde, C. (författare)
-
Prinz, J. C. (författare)
-
- Berg, Mats (författare)
- Uppsala universitet,Dermatologi och venereologi,Centrum för klinisk forskning i Sörmland (CKFD)
-
Kerrouche, N. (författare)
-
Rives, V. P. (författare)
-
visa färre...
-
(creator_code:org_t)
- 2011-10-27
- 2012
- Engelska.
-
Ingår i: Journal of the European Academy of Dermatology and Venereology. - : Wiley. - 0926-9959 .- 1468-3083. ; 26:11, s. 1407-1414
- Relaterad länk:
-
https://urn.kb.se/re...
-
visa fler...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Background Scalp psoriasis is a difficult to treat and usually chronic manifestation of psoriasis. The CalePso study showed that CPS (Clobex ® Shampoo) in maintenance therapy of scalp psoriasis (twice weekly) significantly increases the probability of keeping patient under remission during 6 months, compared with vehicle (40.3% relapses vs. 11.6% relapses, ITT). Objective The objective of the study was to assess the cost-effectiveness of a maintenance therapy with CPS vs. its vehicle in nine European countries. Methods A 24-week decision tree model was developed with 4-weekly time steps. The considered population has moderate scalp psoriasis successfully treated with a daily application of CPS up to 4 weeks. Data were taken from the CalePso study and from national experts' recommendations for alternative treatment choices, with their probabilities of success taken from literature to develop country-specific models. Health benefits are measured in disease-free days (DFD). The economic analysis includes drug and physician costs. A probabilistic sensitivity analysis (PrSA) assesses the uncertainty of the model. Results Depending on the country, the mean total number of DFDs per patient is 21-42% higher with CPS compared with vehicle, and the mean total cost is 11-31% lower. The mean costs per DFD are 30-46% lower with CPS compared with the vehicle. The PrSA showed in 1000 simulations that CPS is more effective vs. vehicle in 100% of the cases and less expensive than its vehicle in 80-99% of the cases. Conclusion This model suggests that CPS is cost-effective in maintaining the success achieved in moderate scalp psoriasis patients.
Nyckelord
- bemethson
- betamethasone
- betamethasone dipropionate
- betamethasone dipropionate plus calcipotriol
- betamethasone valerate
- calcipotriol
- clarelux
- clobetasol propionate
- elucon
- mometasone furoate
- psodermil
- shampoo
- unclassified drug
- xamiol
- article
- cost effectiveness analysis
- drug cost
- Europe
- maintenance therapy
- medical fee
- priority journal
- psoriasis
- relapse
- remission
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas